Nikon Corp. announced on August 3 the financial results for the first quarter ending on June 30, reporting that the total revenue for the period gained a 0.6% year-on-year to 170.3 billion yen, profit in operation declined 31.1% to 12.4 billion yen and net profit down 39.5% to 8.89 billion yen. In the Imaging Products segment, sales of mid-class cameras such as the D7500, a digital SLR camera released in June this year were firm, with unit sales increasing significantly in the U.S. Accordingly, the performance in revenue and operating profit exceeded the planned targets, but compared to the last year, a decease in revenue and operating profit was recorded due to a product mix change caused by the stagnant demand for the D5 and the D500. The company sold 720,000 units of interchangeable-lens cameras, 1.08 million units of interchangeable lenses and 770,000 compact digital cameras. The company said the unit sales of compact digital cameras declined but the average unit price rose about 30%.
Reports suggest that Samsung Electronics will be investing approximately 2 trillion yen by 2021 in order to boost the flash memory production, at its factories in Korea. Samsung intends to secure the top position in the flash memory segment, while Toshiba is still in the process of selling its flash memory business unit— Toshiba Memory. Samsung will be investing in new product lines including its latest NAND type flash memory. The company's production capacity is expected to grow twice by 2021 with this additional investment. According to Research company, IHS Technology, in 2016, Samsung grabbed the top share in the flash memory market with 35.2%, followed by Toshiba 19.3%, Western Digital 15.5%, Micron Technology 12.0%, SK Hynix 10.1% and Intel 6.9% in terms of value.
Japan's leading printer and photocopier maker Konica Minolta Inc. announced at the company will be acquiring Ambry Genetic Corp. - a US diagnostic company, in a deal valued at up to USD 1 billion. This is one of the largest deals for Konica Minolta and the company will jointly carry out the acquisition with the funds provided by Innovation Network Corp of Japan. Konica Minolta, which has a market value of around $4 billion, will account for 60 percent of the investment and the Innovation Network Corp of Japan (INCJ) will provide for the remaining 40 percent. Both the companies intend to enter into the precision medicine segment which is expected to have a great potential for the treatment of cancer. KMI has its own diagnostic technique, utilising a High Sensitive Tissue Testing (HSTT) technology, while Ambry excels in genetic tests for breast, colon and cancers, heart and respiratory diseases, etc. Further, the company will combine its HSTT technology and Ambry's genetic diagnostic technology to offer high-standard cancer diagnostic services and aid the development of new reagents which will help produce new medicines. Talking about the acquisition, Shoei Yamana - Chief Executive Officer of Konica Minolta Inc., said, “Together with Ambry, we will have the most comprehensive set of diagnostic technologies for mapping an individual's genetic and biochemical makeup." The companies expect to complete the necessary procedure for the deal by the end of October, 2017 and post which, Ambry will become a subsidiary of KMI while Ambry's business will be continued in the US.